Literature DB >> 8273542

Prothrombotic effects of endothelin-2 (ET-2).

G W Raff1, C R Spillert, D J Wilson, E J Lazaro.   

Abstract

In this report we demonstrate that ET-2, in addition to its powerful vasoconstrictor properties and its role in hypertension, is capable of creating a hypercoagulable (prothrombotic) state. This study was facilitated by the utilization of a sensitive modified recalcification time (MRT) test that can measure coagulation at all points in the coagulation spectrum. The MRT was determined on aliquots (1 ml) of citrated blood which were added to saline (MRTS), to 10 micrograms of endotoxin (MRTE), and to 10 pg of ET-2 (MRT ET-2). The mean values of MRTS, MRTE, and MRT ET-2 were 4.3 +/- 0.8, 3.7 +/- 1.0, and 3.9 +/- 0.8 min, respectively. There was a statistically significant difference between MRTE vs. MRTS and MRT ET-2 vs. MRTS using the two-tailed t-test (p < 0.02 and p < 0.005, respectively).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8273542     DOI: 10.1007/bf01972735

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  3 in total

1.  Contribution of the monocyte to thrombotic potential.

Authors:  C R Spillert; E J Lazaro
Journal:  Agents Actions       Date:  1991-09

2.  Cold-induced hypercoagulability in vitro: a trauma connection?

Authors:  F J Ferraro; C R Spillert; K G Swan; E J Lazaro
Journal:  Am Surg       Date:  1992-06       Impact factor: 0.688

3.  Modified recalcification time: a global coagulation screening test.

Authors:  C R Spillert; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1993-08       Impact factor: 1.798

  3 in total
  2 in total

1.  Heavy water activates monocyte generation of tissue factor.

Authors:  C R Spillert; R N Gonzales; R Ponnudurai; S Bonthu; E J Lazaro
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

2.  Endotoxin negates anticoagulant effect of cyclosporine.

Authors:  C R Spillert; S Bonthu; R Ponnudurai; M A Miller; E J Lazaro
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.